Arrowhead Pharma Stock Price, News & Analysis

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is set to participate in several key healthcare conferences in June 2022. Events include the Jefferies Healthcare Conference from June 8-10 and the Goldman Sachs 43rd Annual Global Healthcare Conference from June 13-16, both featuring presentations by Vincent Anzalone, Vice President Finance and Investor Relations.

Additionally, they will present at The International Liver Congress™ 2022, discussing significant studies related to chronic hepatitis B. Further details can be accessed through their Events and Presentations webpage.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is hosting a pulmonary R&D Day in New York City to unveil its pipeline of RNA interference therapeutics targeting pulmonary diseases. Key presentations include ARO-MUC5AC, ARO-RAGE, and ARO-MMP7, aimed at treating muco-obstructive and inflammatory conditions. ARO-RAGE shows over 90% mRNA reduction in preclinical studies, while ARO-MUC5AC promises significant silencing of pathogenic expression. ARO-MMP7 targets idiopathic pulmonary fibrosis. The event will enhance confidence in upcoming clinical trials.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported strong financial results for Q2 FY2022, demonstrating a revenue increase to $151.8 million, up from $32.8 million in Q2 FY2021. The company achieved a net income of $44.4 million, or $0.41 per diluted share, compared to a loss of $26.8 million in the previous year. Key developments include the initiation of several clinical studies for its investigational RNA interference therapeutics, which target various conditions, alongside the formation of a joint venture in Greater China and the groundbreaking of a new manufacturing facility.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has commenced construction on a new drug manufacturing facility in Verona, WI, expected to span about 160,000 square feet, alongside a 125,000 square foot laboratory and office space. The company has been awarded $16 million in tax increment financing from Verona and $2.5 million in refundable income tax credits from the Wisconsin Economic Development Corporation. Completion of the lab is anticipated by 2023, while the manufacturing facility is expected to finish in 2024, aiming to support the development of innovative RNAi-based therapies.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) appointed Victoria Vakiener as an independent director, effective May 2, 2022. Vakiener brings extensive experience, including leadership roles at Epizyme and Johnson & Johnson, aimed at guiding Arrowhead's growth in RNAi technology commercialization. Chairman Douglass Given praised her ability to help the company transition into a commercial stage. This strategic addition underscores Arrowhead's commitment to enhancing its leadership as it focuses on advancing its innovative gene-silencing therapies to tackle intractable diseases.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in several upcoming conferences in May 2022. Events include TIDES USA 2022 from May 9-12, where Michael Lawler will discuss scale-up manufacturing. At the American Thoracic Society Conference from May 13-18, David Kasahara will present on RNAi delivery platforms targeting lung inflammation. Arrowhead will also participate in the BofA Securities Healthcare Conference and the RBC Capital Markets Healthcare Conference on May 12 and 17, respectively, both featuring Christopher Anzalone. Further details are available on their website.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a pulmonary research & R&D day on May 26, 2022, from 10:00 a.m. to 1:00 p.m. ET in New York City. The event will discuss its pipeline of pulmonary targeted RNA interference (RNAi) therapies, featuring key opinion leaders, Dr. Mario Castro and Dr. Matthias Salathe. Presentations will cover ARO-MUC5AC and ARO-RAGE, investigational RNAi candidates targeting muco-obstructive and inflammatory pulmonary diseases. Attendance is limited to institutional investors and analysts; RSVP is required.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated the dosing of patients in the Phase 2 GATEWAY clinical study for ARO-ANG3, targeting homozygous familial hypercholesterolemia (HoFH). This RNA interference therapy aims to silence ANGPTL3, a critical protein in lipid metabolism. The study will assess the safety and efficacy of ARO-ANG3 in up to 16 subjects with significant unmet medical needs. Arrowhead is also nearing completion of the Phase 2b ARCHES-2 study, with topline data expected in early 2023.

Arrowhead Pharmaceuticals has formed a joint venture, Visirna Therapeutics, with Vivo Capital to develop four RNAi-based therapies for cardiometabolic diseases in Greater China. Vivo Capital's initial investment amounts to $60 million. Arrowhead retains majority ownership and is eligible for potential royalties on product sales. Visirna will manage local clinical development and has begun recruiting its leadership team in Shanghai to ensure effective engagement with the Chinese biopharma landscape.